HBR

“Reskilling in the Age of AI” Wins 2023 HBR Prize

Retrieved on: 
Tuesday, April 9, 2024
Technology, Human Resources, Publishing, Communications, Professional Services, Business, Training, University, Education, Artificial Intelligence, Harvard Business Review, Boston Consulting Group, Business administration, HBR, Automation, Thought, Organization, Harvard Business School, AI, Doctor of Philosophy, Management

An in-depth study of how companies are reskilling their employees in a rapidly evolving era of automation and AI has won the 2023 HBR Prize, which honors the best Harvard Business Review article of the year.

Key Points: 
  • An in-depth study of how companies are reskilling their employees in a rapidly evolving era of automation and AI has won the 2023 HBR Prize, which honors the best Harvard Business Review article of the year.
  • They interviewed leaders at some 40 organizations around the world that are investing in large-scale reskilling programs.
  • Their analysis revealed five paradigm shifts emerging in reskilling—and the lessons learned from companies that are implementing these shifts.
  • The judging panel recognized three other articles as HBR Prize finalists:

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Retrieved on: 
Wednesday, March 13, 2024
Gram-negative bacteria, Department of Defence, Urinary tract infection, GSK, Patient, Human services, Quality of life, IND, Tebipenem, Clinical trial, Therapy, Infection, Research, Policy, Treasurer, Carbapenem-resistant enterobacteriaceae, Safety, Pharmacokinetics, Federal, Food, AP, Drug discovery, Disease, Kidney, SPA, Acinetobacter baumannii, MDR, Pyelonephritis, Annual report, FDA, Army, HBR, Government, Unitary state, NTM, Assistant, Fungal infection, Pseudomonas aeruginosa, Hope, National Institutes of Health, ID, Mycobacterium avium complex, Bangladesh Technical Education Board, Administration, Pharmaceutical industry

“2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.

Key Points: 
  • “2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.
  • Top-line data from the Phase 2a proof-of-concept clinical trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients is expected in 2H 2024.
  • Spero commenced enrollment in PIVOT-PO, a global, randomized, double-blind, Phase 3 clinical trial of tebipenem HBr in patients with cUTI, including AP in December 2023.
  • Total revenue for the fourth quarter of 2023 was $73.5 million, compared with total revenue of $47.4 million for the fourth quarter of 2022.

Harvard Business Review Analytic Services Survey Highlights Missed Opportunities for Those Without Tuition Assistance Benefits

Retrieved on: 
Wednesday, March 27, 2024
Training, Preschool, Labor, Public Policy, Government, Small Business, Other Education, Continuing, University, Human Resources, Primary, Secondary, Finance, Education, Other Consumer, Banking, Accounting, Professional Services, Consumer, Packaging, Engineering, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Other Policy Issues, Workforce, HBR, McDonnell Aircraft Corporation, Organization, Strategic Education, Inc., Management

Ninety-one percent agree that tuition assistance (TA) benefits programs can give organizations a competitive advantage by upskilling the workforce.

Key Points: 
  • Ninety-one percent agree that tuition assistance (TA) benefits programs can give organizations a competitive advantage by upskilling the workforce.
  • The survey also revealed that nearly 90% of business leadership agree that, for organizations in their industry, there is strategic value in offering tuition assistance benefits to employees.
  • Yet, despite this agreement, the survey highlights an inherent paradox and an opportunity for employers to gain a competitive advantage.
  • Eighty-five percent of the business leadership surveyed agree that the positive outcomes from offering tuition assistance benefits outweigh the costs of paying for employees’ education.

Executive Karla Martin Joins Advisory Board of NYC Fashion Brand Ramy Brook

Retrieved on: 
Wednesday, March 13, 2024
Consumer, Advisory board, Growth, Learning, Woman, Corporate title, HBR, Most, Fortune 500, Harvard Business Review, Creative, Savage X Fenty, Secrecy, Fashion design

NEW YORK, March 13, 2024 /PRNewswire/ -- Ramy Brook, a leading fashion brand known for its luxurious, stylish and sexy contemporary designs, proudly announces the addition of C-Suite advisor and executive Karla Martin to its Advisory Board.

Key Points: 
  • NEW YORK, March 13, 2024 /PRNewswire/ -- Ramy Brook, a leading fashion brand known for its luxurious, stylish and sexy contemporary designs, proudly announces the addition of C-Suite advisor and executive Karla Martin to its Advisory Board.
  • "We are absolutely delighted to have Karla Martin join our Advisory Board," says Ramy Brook Sharp, the Founder and Creative Director behind the eponymous brand.
  • "I am honored to join Ramy Brook's Advisory Board," said Karla Martin.
  • I look forward to working closely with the team to drive innovation and further elevate the Ramy Brook brand."

Tips For Creating a Culture of Appreciation in the Post-Covid Remote Work Era

Retrieved on: 
Wednesday, February 28, 2024
Difference, Message, HBR, News, Gift, Gesture, Motivation, Amazon, Online shopping

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- A recently recirculated HBR article highlights that employees need both recognition and appreciation to feel motivated, noting that there is a big difference between these two often interchangeably used nouns. While recognition is used to praise workplace achievements and is often linked to financial incentive, appreciation is the act of recognizing someone's inherent value, which is fostered through the acts of connection and support.

Key Points: 
  • It is preferable to avoid giving different denominations to individuals based on title, years of work or other factors.
  • While 23% of employers who send gift cards for Employee Appreciation Day send gift cards valued at $25 or greater, the most popular denomination used for Employee Appreciation gift cards in 2023 was just $10 per person!
  • It shows that you are genuinely listening to them and care about what they have to say.
  • In fact, last year, 71% of Employee Appreciation Day campaigns created on the CardSnack's platform were created within 2 days of Employee Appreciation Day!

Terra Balcanica Drills 499 g/t AgEq Over 3.8 m At Cumavici Ridge in Bosnia and Herzegovina and Closes Private Placement Financing

Retrieved on: 
Wednesday, January 17, 2024
Private, Gold, HBR, Digestion, Potassium chlorate, GPS, ICP-AES, PQ3, Silver, Acquisition, Offering, HNO3, Regulation, ISO/IEC, National instrument, News, ALS, Terra

VANCOUVER, British Columbia, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) is pleased to announce additional assay results from the 2023 Phase II drill campaign confirming continuation of the high-grade Cumavici Ridge polymetallic mineralization within its flagship Viogor-Zanik project in Bosnia and Herzegovina. The Company further announces closing of the final tranche of its non-brokered private placement financing (the “Offering”) of shares (the ”Shares”) for total gross proceeds of $212,200.

Key Points: 
  • Further drilling efforts at Cumavici Ridge will aim to connect the shallow high-grade interval reported in this release to the 531 g/t AgEq over 0.75 m and 355 g/t AgEq over 1.10 m reported over 600 m to the northwest (see Company news release dated 5th November 2023).
  • The system remains untested and open to the southwest down-dip which will also be targeted in 2024 drilling.
  • Drillhole section through step out drill fence located 42 m SE of the 2022 discovery holes at Cumavici Ridge.
  • Terra will use the net proceeds of the Offering for working capital and to finance the acquisition of a strategic mineral exploration licence in Bosnia and Herzegovina.

Terra Balcanica Drills 499 g/t AgEq Over 3.8 m At Cumavici Ridge in Bosnia and Herzegovina and Closes Private Placement Financing

Retrieved on: 
Wednesday, January 17, 2024
Private, Gold, HBR, Digestion, Potassium chlorate, GPS, ICP-AES, PQ3, Silver, Acquisition, Offering, HNO3, Regulation, ISO/IEC, National instrument, News, ALS, Terra

Vancouver, British Columbia, Jan. 17, 2024 (GLOBE NEWSWIRE) --  Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) is pleased to announce additional assay results from the 2023 Phase II drill campaign confirming continuation of the high-grade Cumavici Ridge polymetallic mineralization within its flagship Viogor-Zanik project in Bosnia and Herzegovina. The Company further announces closing of the final tranche of its non-brokered private placement financing (the “Offering”) of shares (the ”Shares”) for total gross proceeds of $212,200.

Key Points: 
  • Further drilling efforts at Cumavici Ridge will aim to connect the shallow high-grade interval reported in this release to the 531 g/t AgEq over 0.75 m and 355 g/t AgEq over 1.10 m reported over 600 m to the northwest (see Company news release dated 5th November 2023).
  • The system remains untested and open to the southwest down-dip which will also be targeted in 2024 drilling.
  • Drillhole section through step out drill fence located 42 m SE of the 2022 discovery holes at Cumavici Ridge.
  • Terra will use the net proceeds of the Offering for working capital and to finance the acquisition of a strategic mineral exploration licence in Bosnia and Herzegovina.

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Retrieved on: 
Friday, January 5, 2024
Policy, Federal, Mycobacterium avium complex, MDR, Government, Infection, FDA, Administration, Army, Pyelonephritis, Therapy, HBR, National Institutes of Health, Bank statement, Human services, GSK, Bangladesh Technical Education Board, Assistant, Spero, Patient, Urinary tract infection, Department of Defence, Unitary state, AP, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.

Key Points: 
  • Entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreement
    CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset, clinical-stage, biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need, today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.
  • “We look forward to another productive year for Spero in 2024, having achieved important clinical and regulatory milestones over the past twelve months,” said Sath Shukla, President, and CEO of Spero Therapeutics.
  • Our Phase 2a trial of SPR720 in nontuberculous mycobacterial pulmonary disease is on track, and we look forward to reporting topline data, which is expected in the second half of 2024.
  • The trial is expected to enroll up to 35 treatment-naïve or treatment-experienced non-refractory participants with NTM-PD, due to Mycobacterium avium complex.

Hi-Tech Pharmaceuticals Expands Production Capabilities in Dietary Supplement and OTC Drug Manufacturing

Retrieved on: 
Wednesday, January 3, 2024
Guaifenesin, API, Medication, Cough, CGMP, RTD, Drink, Liquid, HBR, Tablet, Mucus, Rest, Animal Health, OTC, Online shopping

The OTC product (guaifenesin 1200-mg and dextromethorphan HBr 60-mg extended-release tablets) is indicated to control coughs and break up mucus in order to make coughs more productive.

Key Points: 
  • The OTC product (guaifenesin 1200-mg and dextromethorphan HBr 60-mg extended-release tablets) is indicated to control coughs and break up mucus in order to make coughs more productive.
  • Upper respiratory treatments are the single biggest over-the-counter drug category, according to the nonprofit Consumer Healthcare Protection Association.
  • Since 1979, Hi-Tech Pharmaceuticals has been providing quality custom manufacturing services to the pharmaceutical, dietary supplement and beverage industries.
  • Hi-Tech Pharmaceuticals is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products with customers throughout the world.

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, January 2, 2024
Patient, MDR, Sale, Physician, FDA, Tebipenem, Infection, Pyelonephritis, Therapy, HBR, GSK, Spero, Urinary tract infection, AP, Pharmaceutical industry

Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.

Key Points: 
  • Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
  • “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program,” said Sath Shukla, President and CEO of Spero Therapeutics.
  • "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI.
  • The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.